Glycolysis Metabolites and Risk of Atrial Fibrillation and Heart Failure in the PREDIMED Trial

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Glycolysis Metabolites and Risk of Atrial Fibrillation and Heart Failure in the PREDIMED Trial. / Becerra-Tomás, Nerea; Ruiz-Canela, Miguel; Hernández-Alonso, Pablo; Bulló, Mònica; Li, Jun; Guasch-Ferré, Marta; Toledo, Estefanía; Clish, Clary B.; Estruch, Ramon; Ros, Emilio; Fitó, Montserrat; Lee, Chih-Hao; Pierce, Kerry; Arós, Fernando; Serra-Majem, Lluís; Liang, Liming; Razquin, Cristina; Gómez-Gracia, Enrique; Martínez-González, Miguel A.; Hu, Frank B.; Corella, Dolores; Salas-Salvadó, Jordi.

In: Metabolites, Vol. 11, 2021.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Becerra-Tomás, N, Ruiz-Canela, M, Hernández-Alonso, P, Bulló, M, Li, J, Guasch-Ferré, M, Toledo, E, Clish, CB, Estruch, R, Ros, E, Fitó, M, Lee, C-H, Pierce, K, Arós, F, Serra-Majem, L, Liang, L, Razquin, C, Gómez-Gracia, E, Martínez-González, MA, Hu, FB, Corella, D & Salas-Salvadó, J 2021, 'Glycolysis Metabolites and Risk of Atrial Fibrillation and Heart Failure in the PREDIMED Trial', Metabolites, vol. 11. https://doi.org/10.3390/metabo11050306

APA

Becerra-Tomás, N., Ruiz-Canela, M., Hernández-Alonso, P., Bulló, M., Li, J., Guasch-Ferré, M., Toledo, E., Clish, C. B., Estruch, R., Ros, E., Fitó, M., Lee, C-H., Pierce, K., Arós, F., Serra-Majem, L., Liang, L., Razquin, C., Gómez-Gracia, E., Martínez-González, M. A., ... Salas-Salvadó, J. (2021). Glycolysis Metabolites and Risk of Atrial Fibrillation and Heart Failure in the PREDIMED Trial. Metabolites, 11. https://doi.org/10.3390/metabo11050306

Vancouver

Becerra-Tomás N, Ruiz-Canela M, Hernández-Alonso P, Bulló M, Li J, Guasch-Ferré M et al. Glycolysis Metabolites and Risk of Atrial Fibrillation and Heart Failure in the PREDIMED Trial. Metabolites. 2021;11. https://doi.org/10.3390/metabo11050306

Author

Becerra-Tomás, Nerea ; Ruiz-Canela, Miguel ; Hernández-Alonso, Pablo ; Bulló, Mònica ; Li, Jun ; Guasch-Ferré, Marta ; Toledo, Estefanía ; Clish, Clary B. ; Estruch, Ramon ; Ros, Emilio ; Fitó, Montserrat ; Lee, Chih-Hao ; Pierce, Kerry ; Arós, Fernando ; Serra-Majem, Lluís ; Liang, Liming ; Razquin, Cristina ; Gómez-Gracia, Enrique ; Martínez-González, Miguel A. ; Hu, Frank B. ; Corella, Dolores ; Salas-Salvadó, Jordi. / Glycolysis Metabolites and Risk of Atrial Fibrillation and Heart Failure in the PREDIMED Trial. In: Metabolites. 2021 ; Vol. 11.

Bibtex

@article{6e5ba4f85fe84fd2895973589d2b65ea,
title = "Glycolysis Metabolites and Risk of Atrial Fibrillation and Heart Failure in the PREDIMED Trial",
abstract = "The increased prevalence of atrial fibrillation (AF) and heart failure (HF) highlights the need to better understand the mechanisms underlying these cardiovascular diseases (CVDs). In the present study, we aimed to evaluate the association between glycolysis-related metabolites and the risk of AF and HF in a Mediterranean population at high risk of CVD. We used two case–control studies nested within the PREDIMED trial. A total of 512 incident AF cases matched to 734 controls, and 334 incident HF cases matched to 508 controls, were included. Plasma metabolites were quantified by using hydrophilic interaction liquid chromatography coupled with high-resolution negative ion mode MS detection. Conditional logistic regression analyses were performed. The results showed no association between baseline plasma glycolysis intermediates and other related metabolites with AF. Only phosphoglycerate was associated with a higher risk of HF (OR for 1 SD increase: 1.28; 95% CI: 1.06, 1.53). The present findings do not support a role of the glycolysis pathway in the pathogenesis of AF. However, the increased risk of HF associated with phosphoglycerate requires further studies.",
author = "Nerea Becerra-Tom{\'a}s and Miguel Ruiz-Canela and Pablo Hern{\'a}ndez-Alonso and M{\`o}nica Bull{\'o} and Jun Li and Marta Guasch-Ferr{\'e} and Estefan{\'i}a Toledo and Clish, {Clary B.} and Ramon Estruch and Emilio Ros and Montserrat Fit{\'o} and Chih-Hao Lee and Kerry Pierce and Fernando Ar{\'o}s and Llu{\'i}s Serra-Majem and Liming Liang and Cristina Razquin and Enrique G{\'o}mez-Gracia and Mart{\'i}nez-Gonz{\'a}lez, {Miguel A.} and Hu, {Frank B.} and Dolores Corella and Jordi Salas-Salvad{\'o}",
year = "2021",
doi = "10.3390/metabo11050306",
language = "English",
volume = "11",
journal = "Metabolites",
issn = "2218-1989",
publisher = "M D P I AG",

}

RIS

TY - JOUR

T1 - Glycolysis Metabolites and Risk of Atrial Fibrillation and Heart Failure in the PREDIMED Trial

AU - Becerra-Tomás, Nerea

AU - Ruiz-Canela, Miguel

AU - Hernández-Alonso, Pablo

AU - Bulló, Mònica

AU - Li, Jun

AU - Guasch-Ferré, Marta

AU - Toledo, Estefanía

AU - Clish, Clary B.

AU - Estruch, Ramon

AU - Ros, Emilio

AU - Fitó, Montserrat

AU - Lee, Chih-Hao

AU - Pierce, Kerry

AU - Arós, Fernando

AU - Serra-Majem, Lluís

AU - Liang, Liming

AU - Razquin, Cristina

AU - Gómez-Gracia, Enrique

AU - Martínez-González, Miguel A.

AU - Hu, Frank B.

AU - Corella, Dolores

AU - Salas-Salvadó, Jordi

PY - 2021

Y1 - 2021

N2 - The increased prevalence of atrial fibrillation (AF) and heart failure (HF) highlights the need to better understand the mechanisms underlying these cardiovascular diseases (CVDs). In the present study, we aimed to evaluate the association between glycolysis-related metabolites and the risk of AF and HF in a Mediterranean population at high risk of CVD. We used two case–control studies nested within the PREDIMED trial. A total of 512 incident AF cases matched to 734 controls, and 334 incident HF cases matched to 508 controls, were included. Plasma metabolites were quantified by using hydrophilic interaction liquid chromatography coupled with high-resolution negative ion mode MS detection. Conditional logistic regression analyses were performed. The results showed no association between baseline plasma glycolysis intermediates and other related metabolites with AF. Only phosphoglycerate was associated with a higher risk of HF (OR for 1 SD increase: 1.28; 95% CI: 1.06, 1.53). The present findings do not support a role of the glycolysis pathway in the pathogenesis of AF. However, the increased risk of HF associated with phosphoglycerate requires further studies.

AB - The increased prevalence of atrial fibrillation (AF) and heart failure (HF) highlights the need to better understand the mechanisms underlying these cardiovascular diseases (CVDs). In the present study, we aimed to evaluate the association between glycolysis-related metabolites and the risk of AF and HF in a Mediterranean population at high risk of CVD. We used two case–control studies nested within the PREDIMED trial. A total of 512 incident AF cases matched to 734 controls, and 334 incident HF cases matched to 508 controls, were included. Plasma metabolites were quantified by using hydrophilic interaction liquid chromatography coupled with high-resolution negative ion mode MS detection. Conditional logistic regression analyses were performed. The results showed no association between baseline plasma glycolysis intermediates and other related metabolites with AF. Only phosphoglycerate was associated with a higher risk of HF (OR for 1 SD increase: 1.28; 95% CI: 1.06, 1.53). The present findings do not support a role of the glycolysis pathway in the pathogenesis of AF. However, the increased risk of HF associated with phosphoglycerate requires further studies.

U2 - 10.3390/metabo11050306

DO - 10.3390/metabo11050306

M3 - Journal article

VL - 11

JO - Metabolites

JF - Metabolites

SN - 2218-1989

ER -

ID: 347789805